"Precigen’s PAPZIMEOS Shows 83% Durable Response in Long-Term RRP Study"

Precigens PAPZIMEOS treatment demonstrates an impressive 83% durable response rate for recurrent respiratory papillomatosis, showcasing a promising advancement in immunotherapy against human papillomavirus infection.

In a long-term study, 83% of complete responders to Precigens PAPZIMEOS maintained durable responses after a median follow-up of 36 months, indicating effectiveness for RRP.
The results were presented at the American Academy of Otolaryngology-Head and Neck Surgery Foundation, highlighting the potential of PAPZIMEOS in addressing human papillomavirus infection in the respiratory system.
Precigen, valued at $930 million, has seen its stock rise over 240% in the past year, reflecting growing investor interest in innovative therapies targeting the respiratory tract.

Why It Matters

The findings underscore the potential of new immunotherapy options for patients suffering from recurrent respiratory papillomatosis, a condition linked to human papillomavirus infection. As treatments evolve, they may significantly improve patient outcomes and reshape approaches to respiratory system infections.